Pancreatic endocrine tumors: a report on a patient treated with sorafenib
- PMID: 21738352
- PMCID: PMC3124729
- DOI: 10.3346/jkms.2011.26.7.954
Pancreatic endocrine tumors: a report on a patient treated with sorafenib
Abstract
A 31-yr-old man with abdominal pain was diagnosed with a pancreatic endocrine tumor and multiple hepatic metastases. Despite optimal treatment with interferon alpha, a somatostatin analog, local therapy with high-intensity focused ultrasound ablation for multiple hepatic metastases, and multiple lines of chemotherapy with etoposide/cisplatin combination chemotherapy and gemcitabine monotherapy, the tumor progressed. As few chemotherapeutic options were available for him, sorafenib (800 mg/day, daily) was administered as a salvage regimen. Sorafenib was continued despite two episodes of grade 3 skin toxicity; it delayed tumor progression compared to the previous immunotherapy and chemotherapy. Serial computed tomography scans showed that the primary and metastatic tumors were stable. Thirteen months after beginning targeted therapy, and up to the time of this report, the patient is well without disease progression. We suggest that sorafenib is effective against pancreatic endocrine tumors.
Keywords: Chemotherapy; Neuroendocrine Tumors; Sorafenib.
Figures


Similar articles
-
Can sorafenib cause hypothyroidism?J Chemother. 2007 Jun;19(3):352-3. doi: 10.1179/joc.2007.19.3.352. J Chemother. 2007. PMID: 17594936 No abstract available.
-
[Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].Gan To Kagaku Ryoho. 2011 Nov;38(12):2493-5. Gan To Kagaku Ryoho. 2011. PMID: 22202424 Japanese.
-
Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.Clin Drug Investig. 2009;29(1):65-71. doi: 10.2165/0044011-200929010-00007. Clin Drug Investig. 2009. PMID: 19067476
-
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].Z Gastroenterol. 2009 Jan;47(1):55-60. doi: 10.1055/s-0028-1109067. Epub 2009 Jan 20. Z Gastroenterol. 2009. PMID: 19156592 Review. German.
-
Sorafenib (BAY 43-9006): review of clinical development.Curr Clin Pharmacol. 2006 Sep;1(3):223-8. doi: 10.2174/157488406778249325. Curr Clin Pharmacol. 2006. PMID: 18666747 Review.
References
-
- O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008;34:324–332. - PubMed
-
- Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633–2642. - PubMed
-
- Costa F, Domenichini E, Garavito G, Medrano R, Mendez G, O'Connor J, Rojas W, Torres S, Younes RN, Delle Fave G, Oberg K. Management of neuroendocrine tumors: a meeting of experts from Latin America. Neuroendocrinology. 2008;88:235–242. - PubMed
-
- Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008;103:475–483. - PubMed
-
- Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology. 2005;128:1668–1684. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials